论文部分内容阅读
观察免疫缺陷（损）者口服胸腺肽结肠溶制剂后的临床免疫学效果。方法：应用流式细胞术（ＦＣＭ）对５０～６５岁正常中老年人作外用血Ｔ淋巴细胞免疫表型（亚群）的测试普查，用自身对照方法，观察总结筛选的１４例免疫缺陷（损）者在口服胸腺肽结肠溶制剂后外周血Ｔ细胞亚群分布的变化。结果：日服胸腺肽１５ ｍｇ即可有意义地促进免疫缺陷者ＣＤ_３、ＣＤ_４及ＣＤ_８／ＣＤ_８比值的提升，其中ＣＤ_４和ＣＤ_４／ＣＤ_８比值与用药前相比，有非常显著性差异（Ｐ＜０．０１）。结论：临床日服剂量 １５ｍｇ胸腺肽即相当于其注射剂的用量范围，表明口服胸腺肽结肠溶制剂与注射剂的临床效果相当。
To observe the clinical immunological effects of immunodeficient (thymosin) -based oral administration of thymosin and colonic agents. Methods: We used flow cytometry (FCM) to test the immunophenotype (subpopulation) of peripheral blood T lymphocytes in normal middle-aged and elderly people aged 50-65 years. Using self-control method, we observed 14 cases of immunodeficiency Changes in the distribution of T lymphocyte subsets in peripheral blood after oral administration of thymosin colonic-lytic agents. Results: Thymosin 15 mg daily increased the ratio of CD_3, CD_4 and CD_8 / CD_8 in immunocompromised patients. The ratio of CD_4 and CD_4 / CD_8 was significantly different from that before treatment (P <0. 01). Conclusion: Clinical daily dose of 15mg thymosin is equivalent to the range of dosage of its injection, indicating that oral thymosin colonic dissolution and injection of the clinical effect is quite.